The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that Ulipristal acetate is considered Non- Formulary for uterine fibroids
The Medicines and Healthcare products Regulatory Agency (MHRA) guidance for the use of ulipristal for the treatment of uterine fibroids, updated in February 2021, is available here https://www.gov.uk/drug-safety-update/ulipristal-acetate-5mg-esmya-further-restrictions-due-to-risk-of-serious-liver-injury
If a clinician or provider wishes to apply for formulary use of ulipristal for the treatment of uterine fibroids, they may submit a
request by contacting the APC sectretariat at syheartlandsccg.apc@nhs.net
